Addition of docetaxel or bisphosphonates to standard of care in men with localised or metastatic, hormone-sensitive prostate cancer: a systematic review and meta-analyses of aggregate data

BACKGROUND: Results from large randomised controlled trials combining docetaxel or bisphosphonates with standard of care in hormone-sensitive prostate cancer have emerged. In order to investigate the effects of these therapies and to respond to emerging evidence, we aimed to systematically review al...

Descripción completa

Detalles Bibliográficos
Autores principales: Vale, Claire L, Burdett, Sarah, Rydzewska, Larysa H M, Albiges, Laurence, Clarke, Noel W, Fisher, David, Fizazi, Karim, Gravis, Gwenaelle, James, Nicholas D, Mason, Malcolm D, Parmar, Mahesh K B, Sweeney, Christopher J, Sydes, Matthew R, Tombal, Bertrand, Tierney, Jayne F
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Lancet Pub. Group 2016
Materias:
Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4737894/
https://www.ncbi.nlm.nih.gov/pubmed/26718929
http://dx.doi.org/10.1016/S1470-2045(15)00489-1

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4737894/
https://www.ncbi.nlm.nih.gov/pubmed/26718929
http://dx.doi.org/10.1016/S1470-2045(15)00489-1

Ejemplares similares